Mesoblast Ltd., the developer of a cell therapy for steroid-refractory acute graft-vs.-host disease (GVHD), reported that a new analysis of long-term data shows that children treated with the cells demonstrated clinically meaningful responses and significantly increased survival, with an overall response rate of 65 percent at 28 days after treatment.